HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Halozyme Therapeutics Inc (HALO) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company has strong revenue growth and positive analyst sentiment, the significant decline in net income and EPS, coupled with hedge fund selling and lack of recent Intellectia trading signals, suggest a cautious approach. The technical indicators are neutral, and options data reflects a lack of strong bullish sentiment.
The MACD is positive but contracting, RSI is neutral at 54.283, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 68.229), with key support at 65.719.
Analysts have raised price targets significantly, with expectations of continued growth driven by royalty revenues and partnerships.
Hedge funds are selling heavily, with a 4215.85% increase in selling activity last quarter. No recent news or congress trading data to indicate positive sentiment.
In Q4 2025, revenue increased to $451.77M (+51.60% YoY), but net income dropped to -$141.59M (-203.34% YoY), and EPS fell to -1.2 (-213.21% YoY). Gross margin also declined slightly to 77.39% (-3.18% YoY).
Analysts remain optimistic, with Benchmark, Morgan Stanley, and Wells Fargo raising price targets to $90, $94, and $75, respectively. The consensus highlights strong royalty revenues, partnerships, and a stable near-term outlook.
